Strategic Partnerships
Making medicines together. We collaborate with partners to create differentiated antibody medicines.
Our Impact
Making a difference for patients.
Antibody Drug Programs Started
Partners
Candidates Reached the Clinic
Patients Treated Worldwide
Our Partners
We have partnered with innovative biotechs and leading pharmaceutical companies to tackle the toughest problems in drug development.
Our Focus
Developing innovative medicines.
We develop antibody medicines for the most challenging programs in research and development. We are focused on high-value drug classes, targets, and modalities.
We are actively partnering to develop differentiated therapeutics with our T-cell engager platform for oncology and immunology.
Partner Spotlight
Developing next generation radiotherapeutics.
The CEOs of AbCellera and Abdera discuss how our teams developed one of the first VHH antibody-based radiotherapeutics in the clinic, and in just over 3 years.
Get in touch.
We continue to be impressed with the speed of discovery, the quality, and the diversity of the antibodies AbCellera delivers. Through this agreement, we have secured expanded access to an industry-leading technology to accelerate the discovery of antibody-based therapies for patients with neurological diseases.
Alexander Schuth
COO of Denali
AbCellera’s technology enables us to extend our competitive advantage in target discovery and validation with best-in-class antibodies to rapidly advance our programs towards the clinic. We are excited to expand our relationship with AbCellera and to translate many more genetically validated targets into potential new antibody-based therapies together.
Omri Gottesman
MD / CEO and President of Empirico
We are seeing a wave of innovation in the antibody space that is allowing us to add novel functionalities to these molecules. Our partnership with AbCellera will further enable our portfolio companies to pursue these important biologic medicines.
Markus Enzelberger
PhD / Partner at Versant Ventures
AbCellera’s clinically validated platform lets us start discovery in a virtualized model that aligns well with our capital efficient investment strategy. This partnership supports our approach to value creation by allowing us to focus on building companies that aim to deliver impactful medicines to patients.
Steven Robinette
PhD / Venture Partner at Atlas Venture
